Abrocitinib
Abrocitinib
Abrocitinib (pronounced as ab-ro-si-ti-nib) is a Janus kinase inhibitor used in the treatment of atopic dermatitis. It is developed by Pfizer and is currently under clinical trials.
Etymology
The name 'Abrocitinib' is derived from the class of drugs it belongs to, known as Janus kinase inhibitors. The suffix '-nib' is commonly used for these types of drugs.
Usage
Abrocitinib is used for the treatment of moderate to severe atopic dermatitis in patients who are not adequately controlled with topical therapies, or those for whom these therapies are not advisable. It works by inhibiting the Janus kinase enzymes, which play a crucial role in the immune response that leads to inflammation in atopic dermatitis.
Related Terms
- Janus kinase inhibitors: A class of drugs that block the Janus kinase enzymes, which play a crucial role in the immune response that leads to inflammation in various diseases.
- Atopic dermatitis: A type of inflammation of the skin, which results in itchy, red, swollen, and cracked skin.
- Pfizer: An American multinational pharmaceutical corporation, which is one of the world's largest pharmaceutical companies.
Side Effects
Common side effects of Abrocitinib include nausea, diarrhea, and headache. Serious side effects may include infections, increased cholesterol levels, and changes in blood cell counts.
Precautions
Before using Abrocitinib, patients should inform their healthcare provider about any other medications they are taking, as well as any medical conditions they have. It is also important to monitor for any signs of infection while taking this medication.
External links
- Medical encyclopedia article on Abrocitinib
- Wikipedia's article - Abrocitinib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski